Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ9453MR)

This product GTTS-WQ9453MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 0
Species	Chimeric; Humanized
RefSeq	NM_001242867.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3812
UniProt ID	P43630

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9453MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2930MR	IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	AMG888
GTTS-WQ5034MR	IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	CA Exendin-4
GTTS-WQ15428MR	IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	TSR-033
GTTS-WQ12936MR	IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	PankoMab
GTTS-WQ5423MR	IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	CD74-DOX (ADC)
GTTS-WQ2601MR	IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	AMG 531
GTTS-WQ1962MR	IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	AGS-15E
GTTS-WQ2397MR	IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG 110

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST